Menu

Javascript is not activated in your browser. This website needs javascript activated to work properly.
You are here

Tailored Therapy for Chronic Myeloid Leukaemia

Chronic myeloid leukaemia (CML) is a slowly progressing form of blood cancer that attacks the blood-forming cells in the bone marrow. The condition requires lifelong treatment that can cause severe side effects. Rebecca Warfvinge maps stem cells in patients in the hope of identifying predictive markers for how the patient will react to therapy. She has now received an award of USD 20,000 from the biopharmaceutical research company Incyte to conduct her research.

Rebecca Warfvinge.Rebecca Warfvinge. Photo: Åsa Hansdotter. 

Approximately 90 people develop CML in Sweden each year. A genetic abnormality in the Philadelphia chromosome causes the body to produce a protein that in turn signals cells to produce more and more white blood cells.

“Although the disease is chronic, it can be effectively slowed and controlled by medication. Early diagnosis is vital in order to avoid a more acute, difficultto-treat phase,” explains Rebecca Warfvinge, a researcher at the Department of Laboratory Medicine.

Recent decades have seen the development of new and much more effective drugs known as tyrosine kinase inhibitors (TKIs). TKIs block the myeloid-cell-producing protein, meaning that the prognosis for patients is now good, with a survival rate of around 90%. That said, lifelong treatment is required and patients respond differently to the available drugs.

Rebecca Warfvinge uses systematic RNA sequencing of large numbers of individual cells taken from CML patients to map leukaemic stem cells, in order to discover how differences in these can predict how the patient will respond to treatment. The challenge lies in detecting the specific CML genetic mutation in the mixture of healthy and leukaemic stem cells in the bone marrow.

“Our hope is that if we can succeed in identifying specific stem cell markers, these will not only provide an early prognosis for the patient but also have some long-term relevance to our ability to distinguish those patients who can discontinue treatment without risking a relapse,” concludes Rebecca Warfvinge.

Original article published on 12 November 2019

Latest news

3 February 2020

Researchers believe that sugar and obesity can make cancer cells more difficult to kill

Researchers believe that sugar and obesity can make cancer cells more difficult to kill
3 February 2020

Major study gives most comprehensive map of breast cancer risk

Major study gives most comprehensive map of breast cancer risk
3 February 2020

B cells linked to effective cancer immunotherapy

B cells linked to effective cancer immunotherapy
7 January 2020

Prestigious ERC grant for innovative immunotherapy research

Prestigious ERC grant for innovative immunotherapy research
12 December 2019

Tailored Therapy for Chronic Myeloid Leukaemia

Tailored Therapy for Chronic Myeloid Leukaemia

LUCC - Lund University Cancer Centre
Lund University
Box 117, 221 00, Lund, Sweden
Telephone +46 (0) 46 222 0000 (switchboard)